LYON, France--(BUSINESS WIRE)--Regulatory News:
Adocia (Paris:ADOC) (Euronext Paris: FR0011184241- ADOC), the clinical biopharmaceutical company focused on developing innovative formulations of approved proteins for the treatment of diabetes, announced today that two abstracts presenting promising data supporting the ongoing development of two of the Company’s programs, BioChaperone® Lispro and BioChaperone® Glargine GLP-1, have been selected for presentation at the 53rd European Association for the Study of Diabetes (EASD) Annual Meeting to be held September 11 – 15, 2017 in Lisbon, Portugal.
BioChaperone Lispro, Adocia’s most advanced product which is ready to enter Phase 3, is an ultra-rapid acting formulation of insulin lispro. The present study showed that BioChaperone Lispro improved post-prandial glycemic control compared to insulin lispro (Humalog®, Eli Lilly) when repeatedly administered to people with type 1 diabetes for 14 days. Ultra-rapid insulins aim to improve post-prandial glycemic control and to offer greater dosing time flexibility to people with diabetes compared to currently commercialized prandial insulins, such as Humalog®.
BioChaperone Glargine GLP-1s are combinations of the gold-standard basal insulin glargine (Lantus®, Sanofi) with leading GLP-1 receptor agonists (“GLP-1”) dulaglutide (Trulicity®, Eli Lilly) or liraglutide (Victoza®, Novo Nordisk). The present poster demonstrates that the proprietary BioChaperone® technology enables solubilization of insulin glargine at neutral pH, which in turns allows its combination with multiple GLP-1 receptor agonists in solution. In people with type 2 diabetes, 2-in-1 combinations of basal insulin with a GLP-1 have been shown to improve glycemic control over each agent used separately, while reducing side effects.
“The diversity of our portfolio illustrates Adocia’s commitment to address different medical needs for people with diabetes.” commented Dr. Stanislav Glezer, Chief Medical Officer of Adocia “The positive data we present at EASD reflect our efforts in two very distinct treatment options. On the one hand, BioChaperone Lispro is a next-generation prandial insulin that has consistently shown an ultra-rapid-acting profile, which translates into a tighter blood glucose control and supports potential dosing at mealtime. On the other hand, combining gold-standard basal insulin glargine with major GLP-1 products should deliver improved medical outcomes for people with type 2 diabetes who need treatment intensification. We look forward to share this data and further our dialogue with leaders in the diabetes community at the EASD Annual Meeting.”
Details of the posters on BioChaperone Lispro and BioChaperone Glargine GLP-1 are outlined below:
Poster Presentation: Ultra-rapid BioChaperone Lispro improves post-prandial blood glucose excursions versus insulin lispro in a 14-day treatment study in subjects with type 1 diabetes
|Session:||PS 049 Insulin analogues: new insulins|
|Date and Time:||Tuesday, September 12, 12:00 PM - 01:00 PM CEST|
|Presenting Author:||Dr. Grégory Meiffren|
Poster Presentation: BioChaperone technology enables the development of glargine GLP1-RA (liraglutide and dulaglutide) formulations
|Session:||PS 061 Incretins: new formulations|
|Date and Time:||Tuesday, September 12, 12:00 PM - 01:00 PM CEST|
|Presenting Author:||Dr. Rémi Soula|
About the European Association for the Study of Diabetes Annual Meeting
The EASD Annual Meeting is one of the largest European medical meetings dedicated to the latest developments and insights in diabetes and diabetes therapies. The meeting attracts key opinion leaders, company executives, scientists, physicians, researchers, nurses and students interested in diabetes and related subjects. The goal of the EASD Annual Meeting is to encourage excellence in diabetes care through advances in research and education.
Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins. Adocia’s portfolio of injectable treatments for diabetes, featuring five clinical-stage products and five preclinical products, is among the largest and most differentiated of the industry.
The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application in order to address specific patient needs.
Adocia’s clinical pipeline includes four novel insulin formulations for the treatment of diabetes : two ultra-rapid formulations of insulin analogs (BioChaperone Lispro U100 and U200), a rapid-acting formulation of human insulin (HinsBet U100) and a combination of basal insulin glargine and rapid-acting insulin lispro (BioChaperone Combo). Additionally, an aqueous formulation of human glucagon (BioChaperone Human Glucagon) has recently entered clinical testing. Adocia is also developing two combinations of insulin glargine with GLP-1s (BioChaperone Glargine Dulaglutide and BioChaperone Glargine Liraglutide), two combinations of insulin lispro with synergistic prandial hormones (BioChaperone Lispro Pramlintide and BioChaperone Lispro Exenatide), and a concentrated, rapid-acting formulation of human insulin (HinsBet U500), all of which are in preclinical development.
Adocia aims to deliver “Innovative medicine for everyone, everywhere.”
To learn more about Adocia, please visit us at www.adocia.com
This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the “Risk Factors” section of the Reference Document filed with the French Autorité des marchés financiers on April 11, 2017 (a copy of which is available on www.adocia.com) and to the development of economic conditions, financial markets and the markets in which Adocia operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not currently considered material by Adocia. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Adocia to be materially different from such forward-looking statements.
This press release and the information contained herein do not constitute an offer to sell or the solicitation of an offer to buy Adocia shares in any jurisdiction.